Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
The acquisition of Araris follows a 2023 discovery collaboration.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
The Japanese group licenses sapablursen from Ionis for $280m.
Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.
The companies press on with vilastobart and IMPT-314... up to a point.
Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
